What are the symptoms and treatment of Hughes syndrome (Antiphospholipid syndrome)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Hughes syndrome, also known as Antiphospholipid syndrome, is a condition characterized by the presence of antiphospholipid antibodies, which can lead to blood clots, stroke, and other cardiovascular complications, and the primary treatment involves anticoagulation therapy to prevent further clotting events. The symptoms of Hughes syndrome can vary widely, but common manifestations include recurrent miscarriages, thrombocytopenia, and cardiovascular events such as stroke or myocardial infarction 1. The diagnosis of Hughes syndrome is based on the presence of antiphospholipid antibodies, which can be detected by laboratory tests, and the clinical presentation of the patient.

Some key points to consider in the management of Hughes syndrome include:

  • The use of anticoagulant therapy, such as warfarin or heparin, to prevent further clotting events 1
  • The management of cardiovascular risk factors, such as hypertension and hyperlipidemia, to reduce the risk of cardiovascular complications 1
  • The use of aspirin or other antiplatelet agents to prevent blood clots 1
  • The consideration of alternative treatments, such as immunosuppressive therapy, in patients with refractory disease or those who are at high risk of complications 1

In terms of specific treatment recommendations, the use of anticoagulant therapy, such as warfarin or heparin, is the primary treatment for Hughes syndrome, and the goal of treatment is to prevent further clotting events and reduce the risk of cardiovascular complications. The choice of anticoagulant therapy will depend on the individual patient's risk factors and clinical presentation, and the treatment should be tailored to the specific needs of the patient.

It's worth noting that the evidence for the treatment of Hughes syndrome is based on a combination of clinical trials and observational studies, and the optimal treatment approach may vary depending on the specific clinical context. However, the use of anticoagulant therapy is widely recognized as the primary treatment for Hughes syndrome, and it is essential to work closely with a healthcare provider to determine the best course of treatment.

From the Research

Symptoms of Hughes Syndrome (Antiphospholipid Syndrome)

  • The symptoms of Hughes syndrome, also known as antiphospholipid syndrome, can vary widely and may include thrombocytopenia, hemolytic anemia, and acute renal failure 2, 3, 4
  • These symptoms can lead to the development of thrombotic microangiopathy, a condition characterized by the formation of blood clots in small blood vessels 2, 3
  • Other symptoms may include hypertension, headache, vomiting, and renal failure 5, 2

Treatment of Hughes Syndrome (Antiphospholipid Syndrome)

  • The treatment of Hughes syndrome typically involves the use of anticoagulant medications to prevent the formation of blood clots 2, 4
  • In some cases, patients may require plasma exchange or the use of immunosuppressive medications such as corticosteroids 5, 6
  • A new monoclonal anti-C5 antibody, eculizumab, has been shown to be effective in treating atypical hemolytic uremic syndrome (aHUS), a condition that can be associated with Hughes syndrome 5, 4, 6
  • The use of eculizumab has been shown to improve outcomes in patients with aHUS, including reducing the risk of renal failure and improving hemoglobin and platelet counts 5, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Hemolytic uremic syndrome in adults].

Nephrologie & therapeutique, 2010

Research

Haemolytic uraemic syndrome.

Journal of internal medicine, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.